Trastuzumab

• UNSPSC Description:

  Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

• Target Antigen:

  ADC Antibody; EGFR; Radionuclide-Drug Conjugates (RDCs)

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Trastuzumab.html

• Purity:

  99.80

• Solubility:

  H2O

• Smiles:

  [Trastuzumab]

• References & Citations:

  [1]Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70.|[2]Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51.|[3]Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6(7):2065-72.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Store at 4°C for 2 years, do not freeze

• Clinical Information:

  Launched

• CAS Number:

  180288-69-1